The Board of Directors serves as an advisory and oversight board to the American Physician Scientists Association and the Executive Council. The board is made of physician-scientist stakeholders and leaders and of former/current members of the APSA Executive Council. Together this group of individuals not only maintain and guide the long term vision of the organization but they also retain the institutional memory for the organization.
Moshe Levi, MD obtained his degrees in Chemical Engineeringfrom Northwestern University (BS) and Stanford University (MS) and his medical degree from Albert Einstein College of Medicine. He completed his internship and residency training in internal medicine at Cornell Medical College and his fellowship training at the University of Colorado. He was in the faculty in the University of Texas Southwestern Medical Center from 1984-2002 and since 2002 at the University of Colorado where he is currently Professor of Medicine & Physiology and Biophysics & Bioengineering. He is a practicing Nephrologist and he also leads an active research lab investigating 1) the regulation of renal and intestinal phosphate transport, 2) obesity, diabetes and aging related kidney disease, and 3) atherosclerosis and vascular calcification.
Mr. Daniel Dellostritto is a sixth year MD/PhD student at Northeast Ohio Medical University (NEOMED) in Ohio. He completed his undergraduate education at Kent State University (KSU) and in 2010, he graduated Summa Cum Laude with Honors in Integrated Life Sciences. His research at Northeast Ohio Medical University focuses on diabetic oxidative stress and its effects on microvascular function, focusing on its regulation by the TRPV1 (Transient Receptor Potential Vanilloid 1) ion channel. At NEOMED. For his work, Daniel was awarded a prestigious American Heart Association Predoctoral grant. Mr. DelloStritto contributed to the creation of the MD/PhD program and was the co-founder of the local chapter of APSA. Furthermore, he has been involved with the Annual Meeting Planning Committee (2011-2015) as a member in 2011-2012 and a vice-chair for the 2013 Annual meeting and was Co-Chair with Ms. Sherry Wen for the 2014 Annual Meeting. Furthermore, Daniel was elected by to the role of President-Elect for APSA for the 2014-2015 EC and has continued on as President this year. His hopes are to continue to bring APSA to the forefront of physician-science leaders by making sure APSA continues to advocate on behalf of trainees.
Mr. Michael Guo is an MD/PhD candidate at the University of Florida and is currently in the sixth year of his studies. He is pursuing his PhD at Harvard University/Boston Children’s Hospital/Broad Institute in the laboratory of Dr. Joel Hirschhorn, where he studies common and rare genetic variation underlying human anthropometric traits, with a particular focus on height and timing of puberty. Michael is a proud University of Michigan alumnus, graduating in 2010 with degrees in Business Administration and Cellular and Molecular Biology. He previously served as APSA President (2014-2015), President-Elect (2013-2014), and Treasurer (2012-2013).
Jaimo Ahn, MD, PhD is an Assistant Professor of orthopaedic surgery and Co-director of orthopaedic trauma at the Perleman School of Medicine at the University of Pennsylvania. He completed a fellowship in Orthopaedic Traumatology at the Hospital for Special Surgery, Weill Cornell Medical College (2008-2009). He did his internship and residency in orthopaedic surgery at the University of Pennsylvania (2003-2008) where he also received his MD-PhD in Cell & Molecular Biology (1995-2003). Dr. Ahn received his undergraduate degree in Biological Sciences from Stanford University. In addition to studying the education and development of physician-scientists, he co-manages a laboratory with a focus on molecular modulation of bone formation and healing and a clinical research program with a focus on prospective evaluation of orthopaedic trauma outcomes. He is active in medical education, serving as Director of the orthopaedic clerkship, Assistant Director of the orthopaedic residency program, Steering Committee member of the MSTP, all at Penn, and as a member of the USMLE test material development committee, and enjoys reviewing for journals as varied as JAMA, Science Translational Medicine and the Journal of Bone and Joint Surgery. Outside of academics, he especially enjoys food, wine, travel and exercise with his wife. Dr. Ahn became a member of the APSA Board of Directors in April of 2007 and served as Chair in 2011-2013.
Hans Arora, M.D. Ph.D. is urology resident physician at the Cleveland Clinic Foundation Glickman Urological and Kidney Institute. He is a graduate of the Medical Scientist Training Program (MSTP) at the Northwestern University Feinberg School of Medicine, graduating Magna Cum Laude. He received his B.S. with Honors in Chemical Engineering from Pennsylvania State University, and completed his Ph.D. in the laboratory of Dr. Gayle Woloschak in the Department of Radiation Oncology. His dissertation research involved the use of titanium dioxide nanoparticles to overcome cancer chemotherapy drug resistance in ovarian cancer, the number one cause of gynecologic cancer death in women. Specifically he studied the effects of titanium dioxide-doxorubicin nanoconjugates, and their effects on the uptake, localization, and cytotoxicity as compared to free doxorubicin in a drug-resistance ovarian carcinoma model. Interestingly, he found that both free nanoparticles and nanoconjugates increased the uptake of transferrin, a marker for clathrin-mediated endocytosis. His prior research experiences include internships at the National Institutes of Health, the Armed Forces Radiobiology Research Institute, and Pennsylvania State University. His research has been presented at numerous national and international conferences, including the American Society for Radiation Oncology, the American Association for Cancer Research, and the Gordon Conference on Radiation Oncology, and has been supported by national and local research grants from the American Medical Association Foundation, the National Institutes of Health Center for Cancer Nanotechnology Excellence, and the Northwestern University Clinical and Translational Sciences Institute (NUCATS).
Hans continues to be active in the medical community throughout his time as a medical students and resident physician at the national, state, and local levels. He has served as National Chair of the Medical Student Section of the American Medical Association; Physician Advisory Board member of Building a Healthier Chicago; as well as a Trustee of the Illinois State Medical Society, Chicago Medical Society, and the American Physician Scientists Association. For his academic and professional accomplishments, he has been awarded the American Medical Association Foundation Excellence in Leadership Award, the Chicago Medical Society’s inaugural Outstanding Student Award, the Heller Award for Excellence in Clinical Medicine, and was inducted into the Alpha Omega Alpha Honor Medical Society. His continuing research interests involve the molecular mechanisms of disease in urologic oncology.
Lawrence (Skip) Brass, MD PhD is a graduate of Harvard College and Case Western Reserve University, where he received his MD and a PhD in biochemistry. After residency training in internal medicine he became a fellow in Hematology-Oncology at the University of Pennsylvania where he served as Vice Chair for Research in the Department of Medicine from 2004 to 2007, and is currently Professor of Medicine and Pharmacology. Dr. Brass became Associate Dean for Combined Degree and Physician Scholars Programs and Director of Penn’s Medical Scientist Training Program in 1998. He has been active at the national level in the development of training programs for physician-scientists and has served as President of the National Association of MD-PhD Programs, Chair of the AAMC GREAT section on MD-PhD training, and was a member of the NIH Physician-Scientist Workforce advisory group in 2013-2014. He is also a practicing hematologist whose research interests are in the fields of hemostasis and vascular biology. He has been continuously funded by the NIH HLBI since the mid-1980’s, has been elected to membership in the American Society for Clinical Investigation and the Association of American Physicians, was an Established Investigator of the American Heart Association and is a recipient of the Distinguished Career Award from the International Society of Hemostasis and Thrombosis, the Christian R. and Mary F. Lindback Award for Distinguished Teaching from the University of Pennsylvania, and numerous teaching awards from students at the University of Pennsylvania Perelman School of Medicine.
Dania Daye, MD, PhD is completing an internal medicine internship at Brigham and Women’s Hospital prior to pursuing radiology residency at Massachusetts General Hospital. Dr. Daye graduated from the University of Pennsylvania MD-PhD program, with election to Alpha Omega Alpha. She completed her PhD in Bioengineering as an HHMI-NIBIB Interfaces scholar in imaging sciences. The focus of her PhD was on understanding the metabolo-genetic regulation of breast cancer recurrence using multi-nuclear magnetic resonance spectroscopy. As a medical student, Dr. Daye was selected as a Howard Hughes Medical Institute Gilliam fellow and a Paul and Daisy Soros fellow. To date, her research has resulted in a patent, 11 peer-reviewed publications and 45 accepted scientific abstracts at both national and international meetings and a number of invited talks. For her research, Dr. Daye is the recipient of many awards that include the Association of American Physicians Stanley J. Korsmeyer Young Investigator Award, the Association of University Radiologists (AUR) Memorial Award and the Marc Levine Radiology Research Prize. In 2014, she was elected as a junior fellow of the International Society of Magnetic Resonance in Medicine (ISMRM). Ms. Daye served as the 2012-2013 President of the American Physician Scientists Association. During her tenure, she led recruitment efforts that resulted in a 30% increase in membership and in continued APSA representation in 94 U.S. medical schools. Ms. Daye also oversaw the launch of a new APSA website offering improved career development resources for physician-scientist trainees; and fostered a number of new partnerships between APSA and professional societies that included a new partnership with the Radiological Society of North America (RSNA). Ms. Daye previously served as chair and vice-chair of the APSA policy committee and remains involved in APSA’s various policy and data collection initiatives. For her local and national leadership roles, Ms. Daye was the recipient of the 2012 AMA Foundation Leadership Award.
David Engman, MD, PhD is Professor of Pathology and Microbiology-Immunology at Northwestern University Feinberg School of Medicine. He is also head of the Division of Molecular Genetic Pathology at Northwestern Memorial Hospital. Dr. Engman's laboratory has conducted research in the cell and molecular biology and disease pathogenesis of trypanosomes and leishmania for twenty years. Major areas of research include mechanisms of ciliary biogenesis and protein targeting, cell biology of host cell invasion by protozoan parasites and drug discovery for parasitic diseases. Dr. Engman was a Merck American Federation of Clinical Research MD/PhD Fellow and an Established Investigator of the American Heart Association. He is a Member of the American Society for Clinical Investigation and the Pluto Society, and a Fellow of the American Heart Association and the American Academy of Microbiology. He is the recipient of the 2008 Amgen Outstanding Investigator Award of the FASEB American Society for Investigative Pathology. For 17 years, Dr. Engman directed the Northwestern MSTP and also served as President of the National Association of MD-PhD Programs and Chair of the MD-PhD Section of the Association of American Medical Colleges.
Shwayta Kukreti, MD, PhD is resident who will be training in Radiology at UCLA. Currently she is pursuing her preliminary medicine year at the University of Illinois at Urbana-Champaign. In 2011 she completed the Medical Scholars MD/PhD Program at the University of Illinois-Urbana, Champaign. She received her PhD in Biophysics and Computational Biology in 2007 working at the Laboratory for Fluorescence Dynamics in collaboration with the Beckman Laser Institute and Medical Clinic at the University of California-Irvine. Dr. Kukreti's research focus is in biomedical devices, which has led to a patent. More specifically, using lasers she is interested in developing methods for breast imaging and analysis using optical spectroscopy. Dr. Kukreti graduated Bronze Tablet, Summa Cum Laude, with Bachelors of Sciences degrees in Honors Biology and Biochemistry from the University of Illinois-Urbana, Champaign in 2003. She serves a mentor for undergraduate students interested in math, science and engineering. Dr. Kukreti joined APSA as Vice President from 2007-2008. Currently she serves on the Nominations Committee of the APSA Board of Directors.
Dr. David Markovitz is a Professor of Internal Medicine in the Division of Infectious Diseases who also has appointments in the programs in Cellular and Molecular Biology, Cancer Biology, and Immunology. His laboratory focuses on understanding how human cellular factors control the replication of retroviruses such as HIV. These studies are performed both to understand the biology of retroviruses and to develop possible therapies for these important human pathogens, as well as to exploit the viruses as a mechanism for understanding human cellular biology. Current interests in the laboratory focus on four areas: First, the laboratory is studying endogenous human retroviruses, retroviruses that have insinuated themselves into the human genome over the course of millions of years and now make up fully eight percent of our genomes. The Markovitz laboratory is studying whether, contrary to existing dogma, these viruses can still replicate, as well as investigating the role of these viruses in AIDS, cancer, and other diseases. A second project deals with the DEK protein, which is involved in cancer causation and the pathogenesis of juvenile arthritis. Third, the laboratory is working on themolecular engineering of a banana lectin that could be part of a vaginal microbicide used to prevent the sexual spread of HIV and perhaps in the treatment of viral infections. Lastly, the Markovitz research group is studying the role of the intermediate filament protein vimentin in inflammation. These studies are carried out in conjunction with a wide variety of Ph.D. and M.D. trainees, as well as in close collaboration with a number of faculty members from diverse departments at the University of Michigan and other institutions. Dr. Markovitz's work has been recognized by his election to the two principal honorary societies for academic Internal Medicine physicians, the American Society for Clinical Investigation and the Association of American Physicians, and he is the Chair of the Research Committee of the Infectious Diseases Society of America.
Kofi Mensah, MD PhD is currently in his final year of residency in the Yale physician-scientist training program (PSTP) with a clinical fellowship in rheumatology and post-doctoral research fellowship in immunobiology to follow. He is a graduate of the NIH medical-scientist training program (MSTP) at the University of Rochester where he received his PhD in immunology under the direction of Edward Schwarz, PhD and Christopher Ritchlin, MD. Part of his research was funded via the Clinical and Translational Science Institute's Predoctoral Scholar Award. His dissertation looked at immune system regulation of osteoclastogenesis in the context of inflammatory arthritis. His research won first place out of over 1,500 submissions in the basic science research category at the 2006 American College of Physicians National Medical Student Abstract Competition. His dissertation received the Melville A. Hare Award for Distinction in Research (2009). He has also had the honor of presenting his research at the American College of Rheumatology annual meeting, where he spoke as part of the REF Marshall J. Schiff, MD, Memorial Lectureship (2009), as well as at the American Society for Clinical Investigation annual meeting, the American Society for Bone and Mineral Research annual meeting and the American Academy of Orthopaedic Surgeons annual meeting. He is the co-inventor of a novel monoclonal antibody patented for use in the identification of osteoclast precursors. The antibody is currently in clinical testing as an early biomarker of inflammatory arthritis. Dr Mensah is a member of the Alpha Omega Alpha and Phi Beta Kappa honor societies. He has mentored high school, undergraduate, graduate and medical students. As part of his mentorship role, he served as a judge for the 2011 New York City Science and Engineering Fair for high school students. He has also lectured for junior medical students on the topic of immune hypersensitivity reactions. Dr Mensah has been involved with APSA since 2005, when he served as the institutional representative from the University of Rochester. In 2006, he joined the APSA public relations committee where he served as co-editor of the Phi-Psi newsletter (2007-2008). From 2008-2009, he was co-president of the public relations committee and member of the APSA executive council. Beginning in 2014, he serves on the Board of Directors with a strong interest in the physician-scientist career pipeline and establishing partnerships with specialty societies.
M. Kerry O'Banion, MD, PhD is Professor and Associate Chair in the Department of Neurobiology and Anatomy at the University of Rochester School of Medicine & Dentistry. He received his MD-PhD from the University of Illinois at Urbana-Champaign Medical Scholars Program in 1987 and now leads a laboratory focused on understanding the role of neuroinflammation in acute and degenerative brain disease. Dr. O'Banion directs the Medical Scientist Training Program at the University of Rochester and served as Chair of the MD-PhD Section of the Association of American Medical Colleges' Graduate Research, Education, and Training (GREAT) Group in 2009-2010. Dr. O'Banion has been a member of the APSA Board of Directors since March of 2006 and was an advisor to APSA as early as January of 2004 during APSA's initial inception. Dr. O'Banion serves on the Nominations Committee of the APSA Board of Directors and is principal investigator of an R13 grant from the National Cancer Institute that supports APSA's National Meeting.
Eric Schauberger DO, PhD is a PGY-3 resident at the Medical College of Wisconsin/Children's Hospital of Wisconsin Pediatric residency program. He plans to continue in an Allergy/Immunology fellowship after residency. He graduate from the Michigan State University Physician Scientist Training Program in 2012 with his PhD in Genetics. His dissertation title was "The identification of ATPAF1 as a novel asthma susceptibility gene and the characterization of functional regulatory variants".He received his BS in Genetics from Iowa State University in 2003. He was awarded the Senior Leadership award by Iowa State. He has been actively involved at all levels of training and has been involved with APSA leadership including serving as Chair of the Policy committee and member of the Executive Council in 2009-10. He joined the APSA Board of Directors in July of 2011.
Dr. Jill Baren is Chair of the Department of Emergency Medicine and Chief of Emergency Services at the University of Pennsylvania Health System, and Professor of Emergency Medicine and Pediatrics, Perelman School of Medicine at the University of Pennsylvania.
Dr. Baren recently served as President of the Society for Academic Emergency Medicine (www.saem.org), the largest organization in the world solely dedicated to education and research in the specialty. Dr. Baren has lectured extensively, both nationally and internationally. She has published over 80 peer-reviewed articles, editorials and book chapters and is the senior editor of an evidence-based, clinically focused textbook entitled, "Pediatric Emergency Medicine.” Dr. Baren completed a Master of Bioethics degree in the Department of Medical Ethics at the University of Pennsylvania in 2004 and now serves as a faculty in the graduate degree program. She is a nationally recognized expert in the application of the federal regulations for the use of waiver of consent and the emergency exception from informed consent in clinical trials. Dr. Baren’s current research focuses on informed consent and the logistics and special protections of research subjects involved in clinical trials using emergency exception from informed consent. She is the principal investigator of the Greater Philadelphia Southern New Jersey Neurological Emergencies Treatment Trial Network, a consortium of 14 hospitals involving a research team of over 40 individuals.
David Braun, MD, PhD is the former President of APSA. He is currently a resident physician in the Department of Medicine at the Brigham and Women's Hospital and a Clinical Fellow in Medicine at Harvard Medical School. He received his MD with a Distinction in Medical Education from the Icahn School of Medicine at Mount Sinai, where he was the first Sanfurd Bluestein, MD Scholar, and from which he was received the Dr. Barry Coller Award for Excellence in Clinical Medicine. He received his PhD from the Joint Program in Computational Biology at the Courant Insitute of New York University. He graduated Magna Cum Laude from Princeton University with an A.B. in Molecular Biology, and Certificates in Engineering Biology and Computer Science. In addition to his work with APSA, Dr. Braun has served as Co-President of the Mount Sinai Chapter of Physicians for Human Rights, and as the Chief Clinic Manager of the East Harlem Health Outreach Partnership, a student-run clinic that provides free comprehensive medical care to the uninsured. In 2008, Dr. Braun was award the Excellence in Medicine Leadership Award by the American Medical Association Foundation, and the Outstanding Leadership Award by the Mount Sinai School of Medicine. Within APSA, Dr. Braun has served as President, as Chair of the Membership Committee, and as the Institutional Representative for Mount Sinai. In 2007, Dr. Braun initiated and organized the APSA New York Physician Scientists Symposium, which has since become an annual event in the Northeast that draws hundreds of trainees from dozens of institutions each year. His central goal is to help ensure that the enormous promise of translational medicine will be effectively delivered to the community and society at large.
Oscar Cuzzani, MD, DSc is a physician-scientist who specializes in ophthalmology (retina, immunology and glaucoma) with experience in phase 2-3 clinical trials and pharmacovigilance. He has seven years of experience in eye biomechanics with special emphasis in the application of finite element analysis, computational mathematics, and artificial intelligence to develop a virtual biomechanical and optical model of the eye with applications to surgery and soft testing of new compounds/delivery systems in glaucoma. His experience also extends into clinical research in AMD, uveitis (where he evaluated the link between light exposure and breakdown of the blood-ocular barrier with the aim to modulate inflammatory cascades via filtering specific spectra), and anterior segment surgery. From 2007 to 2010, he served as the Director of Clinical Research in the areas of retina and glaucoma and in pharmacovigilance at QLT Inc. From October 2010 to the present, he has served as the Associate Medical Director at Abbott Labs, Abbott Park, IL. Since July 2013 he is Director Global Clinical Development at Allergan Inc, Irvine, CA.
Ophthalmology- Retina, immunology, glaucoma. Start-up in medical devices. Clinicaltrials phases 2-3. Pharmacovigilance. Multidisciplinary teams: computational mathematics,engineering, biomaterials, biosensors, laser interferometry, artificial intelligence, evolutionary modeling. Scientific assessment of emerging drugs for ophthalmology. Ophthalmic, immunologydrug development.
Dr. Michael Zasloff, MD, PhD, a leader in innate immunity, is a Professor of Surgery and Pediatrics at Georgetown University School of Medicine. Dr. Zasloff received his MD, PhD degrees from the New York University Medical Scientist Training Program. He completed his residency training in pediatrics at the Boston Children's Hospital and his post-doctoral training at the NIH in molecular genetics. In 1981, Dr. Zasloff was named Chief of the Human Genetics Branch of the National Institutes of Child Health and Human Development. In 1989, he became the Charles E.H. Upham Professor of Pediatrics and Genetics at the University of Pennsylvania School of Medicine and Chief of the Division of Human Genetics of the Children's Hospital of Philadelphia. He founded Magainin Pharmaceuticals, Inc. in 1988 and served as its Executive Vice President and President of the Magainin Research Institute in 1992. Dr. Zasloff became Vice Chairman of its Board of Directors during 1996-2000. He went on to serve as Dean of Research and Translational Science at the Georgetown University Medical Center, and primarily responsible for the overall management of Georgetown's biomedical research and its translation from the laboratory to patient care. Dr. Zasloff joins the APSA Board of Directors in July of 2009.